Investor Update

Basel, 5 June 2009

Reminder: Roche investor science event from ADA 2009

Phase II data on PPAR co-agonist aleglitazar and overall update on Roche´s diabetes & metabolic diseases pipeline

We kindly invite investors and analysts to participate in a conference call that will be held during the American Diabetes Association (ADA) 69th Scientific Sessions in New Orleans.

On the call, Roche will discuss new phase II data on its PPAR co-agonist aleglitazar (R1439). Further, Roche will provide an overall update on its pipeline and emerging franchise in diabetes and metabolic diseases. The presentation will be followed by a Q&A session.

The conference call will take place on:

Monday, 8 June 2009
8.00 am to 9.30 am  (Central Standard Time)
15.00 pm to 16.30 pm (Europe)
14.00 pm to 15.30 pm (UK)

Investors and analysts are invited to join the conference call either by live audio webcast or by telephone:

Live audio webcast

The live conference call can be accessed via ir.roche.com. Following the event, an MP3 file will be made available for download.

Phone conference call

The live conference call can be accessed using the following dial-in numbers:

+41 91 610 5600 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA – toll free)

Please dial in to the conference call 10 – 15 minutes before the call is scheduled to start.

A replay of the conference call will be available one hour after the conference call and then for 48 hours. The replay can be accessed using the following dial-in numbers:

+41 91 612 4330 (Europe)
+44 207 108 6233 (UK)
+1 866 416 2558 (USA)

Enter the ID 10865 followed by the # sign

At the time of the conference call, the accompanying presentation will be available from the IR website at ir.roche.com.